39061-97-7

Basic information

• Product Name: 4-Chloro-3-nitroquinoline
• Synonyms: QUINOLINE, 4-CHLORO-3-NITRO-;4-CHLORO-3-NITROQUINOLINE;4-Chloro-3-nitroquinoline ,98%;3-Nitro-4-chloroquinoline;4-Chloro-3-nitroqulinoline
• CAS NO: 39061-97-7
• Molecular Formula: C₉H₅ClN₂O₂
• Molecular Weight: 208.6
• EINECS: 1533716-785-6
• Product Categories: pharmacetical;Quinoline&Isoquinoline;API intermediates;Aromatics Compounds;Quinoline;Aromatics;Heterocycles;Intermediates
• Mol File: 39061-97-7.mol
• Article Data: 25

Chemical Properties

• Melting Point: 121-122°C
• Boiling Point: 333.757 °C at 760 mmHg
• Flash Point: 155.651 °C
• Appearance: yellow crystal powder
• Density: 1.484 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.688
• Storage Temp.: -20?C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: -0.28±0.24(Predicted)
• CAS DataBase Reference: 4-Chloro-3-nitroquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-3-nitroquinoline(39061-97-7)
• EPA Substance Registry System: 4-Chloro-3-nitroquinoline(39061-97-7)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 39061-97-7(Hazardous Substances Data)

Usage

Chemical Properties

yellow crystal powder

Uses

4-Chloro-3-nitroquinoline (cas# 39061-97-7) is a compound useful in organic synthesis.

InChI:InChI=1/C9H5ClN2O2/c10-9-6-3-1-2-4-7(6)11-5-8(9)12(13)14/h1-5H

Upstream product

• 50332-66-6 3-nitro-quinolin-4-ol 
• 118-92-3 anthranilic acid 
• 56-57-5 4-nitroquinoline-N-oxide 
• 611-36-9 quinolin-4-ol 
• 2099-63-0 anthranilic acid hydrochloride 
• 121845-92-9 2-<2-nitroethylideneamino>benzoic acid 
• 125836-07-9 3-nitro-4-(1H)-quinolone 

Downstream Products

• 99009-93-5 3-nitro-N-phenylquinolin-4-amine 
• 58401-43-7 3-amino-4-chloroquinoleine 
• 42606-33-7 3-nitro-4-aminoquinoline 
• 99009-85-5 N-(2-methylpropyl)-3-nitro-4-quinolinamine 
• 99009-89-9 4-ethylamino-3-nitroquinoline 
• 129655-57-8 2-methyl-1-(3-nitroquinolin-4-ylamino)propan-2-ol 
• 18527-94-1 (3-nitro-quinolin-4-yl)-phenethyl-amine 
• 99023-70-8 N-benzyl-3-nitroquinolin-4-amine 
• 99010-24-9 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline 
• 99010-63-6 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline 5N-oxide 
• 99010-33-0 1-phenyl-1H-imidazo[4,5-c]quinoline 
• 99010-55-6 1-phenyl-1H-imidazo[4,5-c]quinoline 5-oxide 
• 129655-59-0 1-[(3-amino-4-quinolinyl)amino]-2-methyl-2-propanol 
• 99023-71-9 3-amino-4-(benzylamino)-quinoline 

Relevant articles and documents

Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia

Hair loss is a common dermatosis symptom and side-effect in cancer chemotherapeutics. Imiquimod application at mid and late telogen activated the hair follicle stem cells leading to premature hair cycle entry. Based on quinoline structure, a newly synthesized compound 6b displayed proliferation activity in vitro and in vivo through branch chain replacement and triazole ring cyclization. Toll-like receptors (TLRs) are also critical mediators of the immune system, and their activation is linked to various diseases. The present study aimed to expand new agonists within co-crystallization of TLR7 (PDB code: 5GMH); however, biological assays of NF-κB activity and NO-inhibition indicated that five selected compounds were TLR7 antagonists. Molecular docking indicated the binding mode differences: antagonists binding TLR7 in a different direction and interacting with adjacent TLR7 with difficulty in forming dimers.

IMIDAZOQUINOLINE-TYPE COMPOUNDS AND USES THEREOF

Provided in the present disclosure are imidazoquinoline-type compounds, methods for their preparation, pharmaceutical compositions thereof and their use, wherein the imidazoquinoline-type compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.

SUBSTITUTED IMIDAZOQUINOLINES

The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.